Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.27 -4.5%	$1.35	$1.01 ▼ $3.45	$359.77M	1.12	1.90 million shs	1.98 million shs
MGNX MacroGenics	$1.55 +0.6%	$1.58	$0.99 ▼ $5.77	$97.79M	2.2	870,330 shs	432,663 shs
MREO Mereo BioPharma Group	$2.31 -0.4%	$2.33	$1.58 ▼ $5.02	$367.29M	0.53	1.11 million shs	923,165 shs
RGNX REGENXBIO	$8.33 +1.8%	$7.43	$5.04 ▼ $16.85	$417.48M	1.11	863,289 shs	1.19 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-4.51%	+3.67%	+2.42%	-22.09%	-31.72%
MGNX MacroGenics	+0.65%	+4.38%	+22.05%	-36.99%	-65.17%
MREO Mereo BioPharma Group	-0.43%	-3.35%	+21.58%	-19.79%	-21.96%
RGNX REGENXBIO	+1.83%	+15.06%	+31.60%	+13.80%	-47.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	2.9722 of 5 stars	3.5	2.0	0.0	2.1	3.3	1.3
MGNX MacroGenics	3.6534 of 5 stars	3.2	1.0	4.4	1.8	2.5	0.6
MREO Mereo BioPharma Group	1.7056 of 5 stars	3.6	1.0	0.0	2.5	1.7	0.0
RGNX REGENXBIO	4.1002 of 5 stars	3.4	1.0	4.6	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	3.00	Buy	$4.83	280.58% Upside
MGNX MacroGenics	2.40	Hold	$6.38	311.29% Upside
MREO Mereo BioPharma Group	3.25	Buy	$7.71	233.95% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	279.65% Upside

Current Analyst Ratings Breakdown

Latest MGNX, RGNX, MREO, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	ERAS Erasca	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00
3/21/2025	ERAS Erasca	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$2.10 per share	N/A
MGNX MacroGenics	$148.34M	0.66	N/A	N/A	$2.46 per share	0.63
MREO Mereo BioPharma Group	$1M	367.29	N/A	N/A	$0.36 per share	6.42
RGNX REGENXBIO	$83.33M	5.01	N/A	N/A	$7.09 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$125.04M	-$0.74	N/A	N/A	N/A	N/A	-42.26%	-34.97%	N/A
MGNX MacroGenics	-$9.06M	-$1.08	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	N/A
MREO Mereo BioPharma Group	-$29.47M	-$0.06	N/A	N/A	N/A	N/A	N/A	N/A	5/21/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$4.61	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	N/A

Latest MGNX, RGNX, MREO, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	11.00	11.00
MGNX MacroGenics	N/A	3.75	3.69
MREO Mereo BioPharma Group	N/A	6.10	6.10
RGNX REGENXBIO	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
MGNX MacroGenics	96.89%
MREO Mereo BioPharma Group	62.83%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	21.50%
MGNX MacroGenics	13.00%
MREO Mereo BioPharma Group	5.50%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.29 million	221.94 million	Optionable
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	148.74 million	Optionable
RGNX REGENXBIO	370	50.12 million	43.04 million	Optionable

MGNX, RGNX, MREO, and ERAS Headlines

Recent News About These Companies

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 14 at 7:13 AM | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Integral Health Asset Management LLC

May 14 at 6:17 AM | marketbeat.com

Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Price Target at $31.63

May 14 at 1:53 AM | americanbankingnews.com

FDA Grants Regenxbio Priority Review for MPS II Gene Therapy Regulatory Application

May 13 at 7:10 PM | precisionmedicineonline.com

Regenxbio stock rises on FDA’s priority review for MPS II therapy

May 13 at 7:10 PM | investing.com

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13 at 7:05 AM | prnewswire.com

Cubist Systematic Strategies LLC Makes New $2.79 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 13 at 5:33 AM | marketbeat.com

Brevan Howard Capital Management LP Buys Shares of 41,160 REGENXBIO Inc. (NASDAQ:RGNX)

May 13 at 5:23 AM | marketbeat.com

REGENXBIO Inc.: REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 13 at 4:50 AM | finanznachrichten.de

Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

May 13 at 4:50 AM | finance.yahoo.com

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

May 12 at 6:30 PM | zacks.com

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 12 at 4:05 PM | prnewswire.com

Balyasny Asset Management L.P. Has $9.18 Million Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

May 12 at 4:33 AM | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages

May 12 at 2:51 AM | marketbeat.com

Raymond James Financial Inc. Takes Position in REGENXBIO Inc. (NASDAQ:RGNX)

May 11, 2025 | marketbeat.com

Stifel Financial Corp Buys 39,564 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 10, 2025 | marketbeat.com

5RGNX : What to Expect from Regenxbio's Earnings

May 9, 2025 | benzinga.com

REGENXBIO (RGNX) Projected to Post Quarterly Earnings on Wednesday

May 9, 2025 | marketbeat.com

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 8, 2025 | prnewswire.com

Hsbc Holdings PLC Acquires 48,310 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 8, 2025 | marketbeat.com

REGENXBIO to Participate in Upcoming Investor Conferences

May 6, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, RGNX, MREO, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

$1.27 -0.06 (-4.51%)

As of 05/14/2025 04:00 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

MacroGenics NASDAQ:MGNX

$1.55 +0.01 (+0.65%)

As of 05/14/2025 04:00 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Mereo BioPharma Group NASDAQ:MREO

$2.31 -0.01 (-0.43%)

As of 05/14/2025 04:00 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

REGENXBIO NASDAQ:RGNX

$8.33 +0.15 (+1.83%)

As of 05/14/2025 04:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time